公开(公告)号：US12071425B2

公开(公告)日：2024-08-27

申请号：US17275606

申请日：2019-09-12

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle Braun ,  Cuong Q. Ly ,  Georgette Castanedo ,  Paul Gibbons ,  Wendy Lee ,  Joachim Rudolph ,  Nicole Alice Blaquiere ,  Jacob Bradley Schwarz ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Leo Fu

IPC: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

CPC classification number: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US12275745B2

公开(公告)日：2025-04-15

申请号：US18057742

申请日：2022-11-21

Applicant: Genentech, Inc.

Inventor： Jason Robert Zbieg ,  Paul Powell Beroza ,  Vishal Anil Verma ,  Bing-Yan Zhu ,  Ramsay Beveridge ,  Liang Zhao ,  Melissa Leblanc ,  Lisa Marie Barton ,  Bryan Ka Ip Chan ,  Samir Bouayad-Gervais ,  Anwesha Dey ,  Marie Anne Evangelista ,  Russell Tyler Smith

IPC: C07D513/04 ,  C07D215/12 ,  C07D235/14 ,  C07D239/74 ,  C07D241/42 ,  C07D263/56 ,  C07D307/81 ,  C07D403/06 ,  C07D405/08 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D491/052 ,  C07D498/04

Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

公开(公告)号：US12110276B2

公开(公告)日：2024-10-08

申请号：US18057738

申请日：2022-11-21

Applicant: Genentech, Inc.

Inventor： Jason Robert Zbieg ,  Russell Tyler Smith ,  Paul Powell Beroza ,  Vishal Anil Verma ,  Bing-Yan Zhu ,  Ramsay Beveridge ,  Lisa Marie Barton ,  Bryan Ka Ip Chan ,  Curtis Colwell ,  Samir Bouayad-Gervais ,  Anwesha Dey ,  Marie Anne Evangelista

IPC: C07D231/56 ,  C07D471/04 ,  C07F9/09

CPC classification number: C07D231/56 ,  C07D471/04 ,  C07F9/095

Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

公开(公告)号：US20230057166A1

公开(公告)日：2023-02-23

申请号：US17275606

申请日：2019-09-12

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle Braun ,  Cuong Q. Ly ,  Georgette Castanedo ,  Paul Gibbons ,  Wendy Lee ,  Joachim Rudolph ,  Nicole Alice Blaquiere ,  Jacob Bradley Schwarz ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Leo Fu

IPC: C07D401/14 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  A61K45/06

Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20230047209A1

公开(公告)日：2023-02-16

申请号：US17366923

申请日：2021-07-02

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle Braun ,  Georgette Castanedo ,  Paul Gibbons ,  Joachim Rudolph ,  William Vernier ,  Ramsay Beveridge ,  Yao Wu ,  Guosheng Wu

IPC: C07D471/04 ,  C07D475/00

Abstract: Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.

公开(公告)号：US11028075B2

公开(公告)日：2021-06-08

申请号：US16283451

申请日：2019-02-22

Applicant: GENENTECH, INC.

Inventor： Daniel Sutherlin ,  Steven McKerrall ,  Kwong Wah Lai ,  Zhiguo Liu ,  Wenfeng Liu ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Liang Zhao ,  Claudio Sturino

IPC: C07D413/12 ,  C07D403/12 ,  C07D233/96 ,  C07D401/12 ,  A61P17/04 ,  C07D263/52 ,  C07D305/06 ,  C07D401/14 ,  A61K31/506 ,  A61K31/538 ,  C07B59/00 ,  A61K31/63 ,  A61K45/06 ,  C07D239/69 ,  A61K31/505

Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain. The following compound is illustrative:

公开(公告)号：US10457654B2

公开(公告)日：2019-10-29

申请号：US15799771

申请日：2017-10-31

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Daniel Sutherlin ,  Steven McKerrall ,  Michael Scott Wilson ,  Kwong Wah Lai ,  Philippe Bergeron ,  Birong Zhang ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Liang Zhao ,  Claudio Sturino

IPC: C07D285/08 ,  C07D277/52 ,  C07D239/69 ,  C07D213/76 ,  C07D261/16 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  A61K31/427 ,  A61P19/02 ,  A61P29/00

Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US12209075B2

公开(公告)日：2025-01-28

申请号：US17056325

申请日：2019-05-21

Applicant: GENENTECH, INC.

Inventor： Steven McKerrall ,  Ramsay Beveridge ,  Kwong Wah Lai ,  Philippe Bergeron

IPC: C07D401/12 ,  A61K9/00 ,  A61P17/04 ,  A61P29/00

Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables Y1-Y6, X, Z, Z1, Z2, R2-R3, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. The compounds have sodium channel blocking activity that are useful for treating sodium channel-mediated diseases, in particular for treating pain.

公开(公告)号：US20230202984A1

公开(公告)日：2023-06-29

申请号：US18057738

申请日：2022-11-21

Applicant: Genentech, Inc.

Inventor： Jason Robert Zbieg ,  Russell Tyler Smith ,  Paul Powell Beroza ,  Vishal Anil Verma ,  Bing-Yan Zhu ,  Ramsay Beveridge ,  Lisa Marie Barton ,  Bryan Ka lp Chan ,  Curtis Colwell ,  Samir Bouayad-Gervais ,  Anwesha Dey ,  Marie Anne Evangelista

IPC: C07D231/56 ,  C07D471/04 ,  C07F9/09

CPC classification number: C07D231/56 ,  C07D471/04 ,  C07F9/095

Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

公开(公告)号：US10968203B2

公开(公告)日：2021-04-06

申请号：US15989008

申请日：2018-05-24

Applicant: Genentech, Inc. ,  The Regents of the University of California

Inventor： Marie-Gabrielle Braun ,  Paul Gibbons ,  Wendy Lee ,  Cuong Ly ,  Joachim Rudolph ,  Jacob Schwarz ,  Avi Ashkenazi ,  Leo Fu ,  Tommy Lai ,  Fei Wang ,  Ramsay Beveridge ,  Liang Zhao

IPC: A61K31/506 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P35/00

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.